Epalrestat

Epalrestat is a medical substance classified as an aldose reductase inhibitor. It is primarily used in the treatment of diabetic neuropathy, a condition that affects individuals with diabetes and causes nerve damage. Epalrestat helps to prevent the accumulation of sorbitol in the nerves, a process that can lead to nerve damage and pain.
Diabetic neuropathy is a common complication of diabetes, affecting around 50% of people with the condition. The nerves in the body can become damaged over time due to high blood sugar levels, leading to symptoms such as pain, numbness, tingling, or weakness in the affected areas. This can impact a person’s ability to perform daily tasks and significantly reduce their quality of life.
Epalrestat works by inhibiting the enzyme aldose reductase, which is responsible for converting glucose into sorbitol. When glucose levels are high, as in the case of diabetes, the enzyme becomes overactive, leading to an excessive buildup of sorbitol. This accumulation can cause nerve damage and contribute to the development of diabetic neuropathy.
By inhibiting aldose reductase, Epalrestat reduces the formation of sorbitol, thereby preventing nerve damage and alleviating the symptoms of diabetic neuropathy. This medication is usually prescribed as part of a comprehensive treatment plan that may also include lifestyle modifications, such as maintaining a healthy diet and regular exercise, as well as blood sugar monitoring and management.
Epalrestat is not a cure for diabetic neuropathy, but rather a means of managing and potentially slowing the progression of the condition. As with any medication, follow the prescribed dosage and consult with a healthcare professional about any potential side effects or interactions with other medications.